相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The ganglioside antigen GD2 is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting
S. Kailayangiri et al.
BRITISH JOURNAL OF CANCER (2012)
Combination strategies to enhance antitumor ADCC
Holbrook E. Kohrt et al.
IMMUNOTHERAPY (2012)
Intratumoral hu14.18-IL-2 (IC) Induces Local and Systemic Antitumor Effects That Involve Both Activated T and NK Cells As Well As Enhanced IC Retention
Richard K. Yang et al.
JOURNAL OF IMMUNOLOGY (2012)
Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
Thorsten Simon et al.
BMC CANCER (2011)
Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers
Lei Wu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
F. Navid et al.
CURRENT CANCER DRUG TARGETS (2010)
Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study
Suzanne Shusterman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.
Alice L. Yu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia
Linda S. Sorkin et al.
PAIN (2010)
The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells
Aleksandra Kowalczyk et al.
CANCER LETTERS (2009)
Immunogenicity of the Hu14.18-IL2 Immunocytokine Molecule in Adults With Melanoma and Children With Neuroblastoma
Jacquelyn A. Hank et al.
CLINICAL CANCER RESEARCH (2009)
Phase I Study of ch14.18 With Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-2 in Children With Neuroblastoma After Autologous Bone Marrow Transplantation or Stem-Cell Rescue: A Report From the Children's Oncology Group
Andrew L. Gilman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Clinical pharmacokinetics of bevacizumab in patients with solid tumors
Jian-Feng Lu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma
Julia A. Messina et al.
PEDIATRIC BLOOD & CANCER (2006)
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
W Hiddemann et al.
BLOOD (2005)
Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer
R Bruno et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial
CM Ng et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma
R Niwa et al.
CANCER RESEARCH (2004)
Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma
T Simon et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Enhanced activity of Hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy
ZC Neal et al.
CLINICAL CANCER RESEARCH (2004)
The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity
T Shinkawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-jun terminal kinase) activation
S Yoshida et al.
JAPANESE JOURNAL OF CANCER RESEARCH (2002)
Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma
B Kremens et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2002)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Phase I study of chimeric human/murine anti-ganglioside GD2 monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation:: A Children's Cancer Group Study
MF Ozkaynak et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Confidence interval criteria for assessment of dose proportionality
BP Smith et al.
PHARMACEUTICAL RESEARCH (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
